Background—Apelin is among the most potent stimulators of cardiac contractility known.
However, no physiological or pathological role for apelin–angiotensin receptor-like 1 (APJ) …

Apelin is the endogenous ligand for the previously orphaned G protein-coupled receptor,
APJ. This novel peptidic signalling pathway is widely represented in the heart and …

Apelin is a novel peptide that acts through the APJ receptor, sharing similarities with the
angiotensin II–angiotensin II type 1 receptor pathway. It is a peripheral vasodilator, powerful …

Background: Apelin, the novel endogenous ligand for the G‐protein‐coupled receptor APJ,
has shown positive inotropic, vasodilatory and diuretic properties in animal studies …

Objective: The endogenous peptide apelin is differentially regulated in cardiovascular
disease but the nature of its role in cardiac function remains unclear. Methods: We …

Apelin, the endogenous ligand for the G-protein-coupled APJ receptor, is emerging as a key
hormone in cardiovascular homoeostasis. It is expressed in a diverse range of tissues with …

Cardiac apelin has recently been suggested to contribute to the pathophysiology of heart
failure (HF) in humans. In animal experiments, its infusion acutely improved systolic as well …

Apelin is a recently discovered vasoactive peptide that has been demonstrated to be the
endogenous ligand of the APJ receptor. It was named'apelin'after APJ endogenous ligand …

Background and purpose: The aim of this study was to determine whether the apelin/APJ
system is altered in human cardiovascular disease by investigating whether the expression …

Studies have shown significant cardiovascular effects of exogenous apelin administration,
including the potent activation of cardiac contraction. However, the role of the endogenous …